Ecolab Q3 EPS Miss Estimates; Warns On Macroeconomic Uncertainties

Comments
Loading...
  • Ecolab Inc ECL reported third-quarter FY22 sales growth of 10% year-on-year to $3.669 billion, marginally beating the consensus of $3.66 billion.
  • Sales from Global Industrial rose 16%, Global Institutional & Specialty climbed 12%, Global Healthcare & Life Sciences grew 34% Y/Y in fixed currency.
  • Adjusted EPS of $1.30 missed the analyst consensus of $1.31.
  • Selling, general and administrative expenses rose 5% Y/Y. The operating margin was 13.2%, and operating income for the quarter rose 4% to $483 million.
  • The company held $112.9 million in cash and equivalents as of September 30, 2022.
  • Ecolab said it is preparing for a more challenging macroeconomic environment, especially in Europe, with high delivered product costs and unfavorable currency translation impacts that are expected to persist well into 2023.
  • ECL expects to deliver a continued strong acceleration in Q4 operating income growth. It sees Q4 adjusted EPS approaching last year's $1.28, below the consensus of $1.49.
  • Price Action: ECL shares are trading lower by 8.79% at $143.35 on the last check Tuesday.
  • Photo Via Wikimedia Commons
ECL Logo
ECLEcolab Inc
$236.951.89%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
69.73
Growth
58.42
Quality
64.13
Value
16.93
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In: